Loading candles…
Gufic Biosciences Limited operates in the pharmaceuticals, medicinal chemicals, and botanical products industries. The company is involved in manufacturing pharmaceutical formulations, active pharmaceutical ingredients (APIs), lyophilized injections, medicinal chemicals, and botanical products. It is recognized as one of the largest manufacturers of lyophilized injections in India. Gufic Biosciences offers its products and services through three main segments: domestic branded marketing, contract manufacturing (CMO), and international operations. The company serves markets in India as well as more than 20 countries internationally. No information is available regarding the company's incorporation year, founders, key management, subsidiaries, or stock exchange listings.
This page is a live market overview for GUFIC BIOSCIENCES LTD. (GUFICBIO) on the NSE. As a listed security, GUFIC BIOSCIENCES LTD. is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for GUFICBIO before placing trades on tick2trade.
As of the latest feed, GUFICBIO last traded at ₹421.4 on NSE, up ₹17.05 (4.22%) from the previous close of ₹404.35. Today's session range is ₹404.65 – ₹423.25, against a 52-week band of ₹268 – ₹448. Traded volume today stands at 2.66L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for GUFICBIO in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether GUFICBIO is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for GUFIC BIOSCIENCES LTD. before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in GUFICBIO. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated GUFICBIO option chain page linked from this overview.
| Unaudited Results - Q3-FY25 | To consider and approve Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Nine months ended December 31, 2025 and other business … | 13 Feb 2026 |
| Unaudited Results - Q2 & FY25 | To consider and approve the Unaudited financial results for the Quarter and half year ended September 30, 2025 and other business matters | 14 Nov 2025 |
| Unaudited Results - Q1-FY25 | To consider and approve the unaudited financial results for the quarter ended Jun 30, 2025 and other business matters | 13 Aug 2025 |
| Audited Results - Q4 & FY25 | To consider and approve, inter alia, Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2025, and to … | 30 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.